Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 19, 2024International Journal of Molecular SciencesOpen Access

The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAdam SzpechcińskiJMJoanna Moes-SosnowskaPSPaulina Skronska

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Szpechciński et al. (2024) studied this question.

synapsesocial.com/papers/68e5fb6fb6db64358758f245https://doi.org/10.3390/ijms25147908
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel2019 · 51 citations
  2. 2Is tissue still the issue in detecting molecular alterations in lung cancer?2020 · 60 citations
  3. 3Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening2023 · 4 citations
  4. 4Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 20212022 · 39 citations
  5. 5VarSome: the human genomic variant search engine2018 · 1,951 citations